FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a compound of general formula 
and its pharmaceutically acceptable salts and stereoisomers possessing anti-cancer activity, a based pharmaceutical composition, using them and a method of treating cancer with using them. In general formula I R1 and R2 are specified in hydrogen and halogen; R3, R5, R6, R7, R11, R12, R14 and R15 mean hydrogen; R4 means -OH; R8, R9 and R17 mean unsubstituted C1-C6 alkyl; R10 is specified in hydrogen, =O and ORb, wherein Rb means unsubstituted C1-C6 alkyl; R13 is specified in unsubstituted C1-C6 alkyl, OH-substituted C1-C6 alkyl and COH; R16 means -OH; and the line ----- represents either a bond, or an epoxy group.
EFFECT: producing pharmaceutically acceptable salts and stereoisomers possessing anti-cancer activity.
17 cl, 10 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTITUMOUR COMPOUNDS | 2008 |
|
RU2493147C2 |
| ANTICANCER DIHYDROPYRAN-3-ONE COMPOUNDS | 2007 |
|
RU2444519C2 |
| ANTITUMOUR COMPOUNDS | 2006 |
|
RU2428425C2 |
| METHOD FOR PRODUCING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANE ACIDS, ESTERS AND AMIDES | 2012 |
|
RU2764667C2 |
| PYRAZOLOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | 2015 |
|
RU2733400C2 |
| METHOD OF PRODUCING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | 2012 |
|
RU2602083C2 |
| NEUROACTIVE COMPOUNDS AND THEIR APPLICATION METHODS | 2015 |
|
RU2764702C2 |
| MACROCYCLIC TYROSINE KINASE INHIBITOR AND ITS USE | 2019 |
|
RU2798231C2 |
| ANTIBODY DRUG CONJUGATES | 2014 |
|
RU2669812C2 |
| TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | 2009 |
|
RU2561104C2 |
